ProMIS Neurosciences to Present New Preclinical Data for PMN310 at AD/PD 2023


Presentation Details:


Title: Differentiation of PMN310 from Other Amyloid-Beta-Directed Antibodies: Ability to Selectively Target Toxic Brain Oligomers Despite Competing Monomers and Plaque


The virtual poster (P0214) will be available during the AD/PD 2023 medical conference starting March 28, 2023 and available on ProMIS’ website.


About ProMIS Neurosciences Inc.


ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform – ProMIS™ and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.


For further information:

Visit us at

Please submit media inquiries to [email protected]


For Investor Relations, please contact:

Stern Investor Relations

Suzanne Messere, Managing Director

[email protected]

Tel. 212 698-8801